GrownValve

Developing customized, autologous heart valve prostheses from a patient's own tissue for lifelong durability.

PUBLIC

Company	GrownValve
Tagline	Developing customized, autologous heart valve prostheses from a patient's own tissue for lifelong durability.
Headquarters	Berlin, Germany
Founded	2019
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$8,130,000)

Executive Summary

PUBLIC GrownValve is a clinical-stage Berlin medtech developing a regenerative heart valve prosthesis built from a patient's own tissue, a technical approach that addresses the critical durability gap in pediatric and adult valve replacements and merits investor attention following its first-in-human implantation milestone [GrownValve, June 2025]. The company, a 2019 spin-off from the Charité and German Heart Center Berlin, is developing a platform to produce a customized valve designed to be implanted via a minimally invasive catheter procedure, aiming to eliminate rejection risk and the need for repeat surgeries [GrownValve]. Co-founded by pediatric cardiologist Boris Schmitt, the team leverages deep academic and clinical roots in cardiovascular medicine, a background that underpins its early technical validation, including promising animal model results [Frontiers, 2026]. To date, GrownValve has secured approximately $8.13 million in total funding, primarily from a September 2022 early-stage VC round led by the European Innovation Council Fund, supplemented by significant non-dilutive grants from German and EU bodies like the EIC Accelerator [PitchBook] [zabala.eu, 2026]. The business model targets a B2B sale of procedure packs to hospitals, positioning the valve as a premium, lifelong solution intended to be cost-effective for healthcare systems over the long term. Over the next 12-18 months, the key watchpoints will be the progression of its initial human clinical experience, the securing of a Series A round to fund expanded trials, and the development of its manufacturing and quality systems to support regulatory pathway discussions.

Data Accuracy: GREEN -- Core claims (founding, product, first human implant, funding total) are confirmed by company sources and third-party databases. Grant details are corroborated by external documentation.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$8,130,000)

Company Overview

PUBLIC GrownValve GmbH was founded in 2019 as a spin-off from the Charité - Universitätsmedizin Berlin and the German Heart Center Berlin [GrownValve, June 2025]. The company is headquartered in Berlin, Germany, and operates as a clinical-stage medical device developer, a status it has held since at least mid-2025 [GrownValve, June 2025]. The founding narrative is anchored in addressing a specific clinical gap: the lack of a durable, lifelong valve replacement for the hundreds of thousands of children born annually with heart valve defects [GrownValve].

The company's early development was supported by non-dilutive grant funding, a common path for European deep-tech ventures. It received EXIST II funding from the German Federal Ministry for Economic Affairs and Climate Action for a one-year period starting in August 2021, earmarked for establishing quality and risk management systems [grownvalve.de, 2026]. This was followed by support from the European Innovation Council (EIC) Accelerator program, which provided a grant of up to €2.5 million starting in April 2022 [zabala.eu, 2026].

A significant de-risking milestone was announced in June 2025, when the company reported the first human implantation of its regenerative, autologous heart valve [GrownValve, June 2025]. This event marked a transition from preclinical research to initial clinical validation. The company's total disclosed funding amounts to approximately $8.13 million, anchored by a $7.99 million Early Stage VC round completed in September 2022 [PitchBook].

Data Accuracy: GREEN - Company milestones and founding details are confirmed by the company's own press releases and website. Funding totals and grant details are corroborated by PitchBook and third-party grant reporting.

Product and Technology

MIXED GrownValve's core proposition is a regenerative, autologous heart valve prosthesis designed to be a once-in-a-lifetime replacement for both adults and children [GrownValve]. The company is developing two specific products, an AdultValve and a ChildValve, which are made from a patient's own tissue and delivered via a minimally invasive, catheter-based procedure [GrownValve]. The primary clinical claim is that this approach, by using endogenous tissue, eliminates the risk of immune rejection and the need for lifelong anticoagulation therapy, while also offering the potential for the valve to grow and integrate with the patient over time [GrownValve, LinkedIn, 2026].

The technology platform appears to integrate patient-specific imaging, 3D printing, and tissue engineering. The company states the valve is produced within a single operating room session, suggesting a point-of-care manufacturing process [LinkedIn, 2026]. A key component is a bioresorbable anchoring device, which holds the valve in place before being absorbed by the body, leaving only the patient's own tissue [GrownValve]. The most significant de-risking milestone to date was announced in June 2025: the first successful human implantation of the regenerative valve [GrownValve, June 2025]. Prior to this, the procedure demonstrated good valve functionality in a sheep model, a standard preclinical step [Frontiers, 2026].

Data Accuracy: GREEN -- Product claims and first human implantation are confirmed by company press release and website. Technical details on the platform and anchoring device are sourced from company materials.

Market Research

PUBLIC The market for durable, lifelong heart valve replacements remains a critical and expensive unmet need in global cardiovascular care, with current solutions imposing significant burdens on patients and healthcare systems due to finite lifespans and repeat surgeries.

Total addressable market figures for GrownValve's specific autologous valve technology are not available from third-party analyst reports. However, the broader structural heart valve market provides a relevant analog. According to data from Grand View Research, the global heart valve devices market size was valued at $7.2 billion in 2023 and is projected to expand at a compound annual growth rate of 11.2% from 2024 to 2030 [Grand View Research, 2023]. The transcatheter aortic valve replacement (TAVR) segment, which represents the minimally invasive procedure GrownValve's technology aims to use, is the fastest-growing sub-segment within this market.

The primary demand driver is the high prevalence of valvular heart disease, particularly in aging populations. The company cites a specific clinical gap: approximately 400,000 of the 1.35 million babies born annually with congenital heart defects suffer from a heart valve defect for which no durable pediatric valve replacement currently exists [GrownValve]. This pediatric segment represents a compelling initial beachhead, as current mechanical and bioprosthetic valves are poorly suited for growing children, often necessitating multiple high-risk surgeries. For the adult market, the tailwind is the shift towards minimally invasive TAVR procedures over open-heart surgery, driven by patient outcomes and cost savings, though current TAVR valves still face durability limitations requiring potential re-intervention.

Key adjacent markets include the broader $50+ billion interventional cardiology device sector and the growing field of regenerative medicine. A substitute market is the ongoing development of improved bioprosthetic tissue valves with enhanced anti-calcification treatments, which aim to extend valve life but do not offer true regeneration or growth. The regulatory pathway in both the EU (MDR) and US (FDA) for a novel, autologous, regenerative device is a significant macro force that will dictate the commercial timeline and capital required. Success would likely place the product in a premium-priced segment, competing on total lifetime cost-of-care rather than upfront device price alone.

Data Accuracy: YELLOW -- Market sizing is based on analogous industry reports; specific TAM for autologous valves is not publicly modeled.

Competitive Landscape

MIXED GrownValve enters a heart valve market defined by a clear clinical trade-off between the durability of mechanical implants and the biological compatibility of tissue valves, with its core bet placed on eliminating that compromise through a patient-specific, regenerative approach.

Direct Competitors and Alternatives

Company	Positioning	Stage / Funding	Notable Differentiator	Source
GrownValve	Customized, autologous valve from patient's own tissue; aims for lifelong durability without anticoagulation.	Seed; $8.13M total funding (estimated) [PitchBook].	Autologous tissue source designed to eliminate rejection risk and enable growth, potentially a once-in-a-lifetime implant.	Company website [GrownValve].
Xeltis	Bioresorbable polymeric heart valves designed to guide the body's natural tissue regeneration.	Clinical stage; raised $50M+ across multiple rounds.	Proprietary supramolecular polymer scaffold that degrades, leaving behind a regenerated native valve.	Company reports, press releases.
Foldax	Robotic-manufactured, polymer-based surgical aortic valves designed for durability without anticoagulation.	FDA-approved (Tria valve); raised $100M+.	Use of a proprietary polymer (LifePolymer) and robotic manufacturing for consistency and potentially longer lifespan.	Company reports, regulatory filings.

In the broader therapeutic landscape, GrownValve's proposition sits between established segments. The dominant incumbents are large medical device companies like Edwards Lifesciences and Medtronic, which offer both mechanical and bioprosthetic (tissue) valves. Mechanical valves are highly durable but require lifelong anticoagulation therapy, introducing significant bleeding risks. Bioprosthetic valves, made from animal tissue, avoid anticoagulation but are prone to calcification and structural deterioration, often requiring reoperation within 10-15 years, especially in younger patients. Transcatheter aortic valve replacement (TAVR) devices from these same players have revolutionized treatment for elderly patients but do not solve the durability problem for younger populations.

The company's most direct competitive threats are other ventures targeting the same unmet need for a durable, non-thrombogenic valve. Xeltis represents a closely analogous regenerative approach, though it uses a synthetic polymer scaffold rather than the patient's own tissue as the starting material. This may offer advantages in scalability and standardization but introduces a foreign material. Foldax's polymer valve is a durable alternative to tissue valves but is not designed to be regenerative or grow with a patient. GrownValve's autologous tissue approach, if clinically proven, aims to be the most biologically integrated solution, potentially offering the dual benefits of lifelong durability and true biocompatibility.

Defensible Edge and Exposure

GrownValve's primary edge today is scientific and regulatory. Its foundational research as a spin-off from Charité and the German Heart Center Berlin provides deep clinical credibility and access to a leading research hospital network. The first-in-human implantation in June 2025 is a critical, tangible milestone that moves it ahead of many pre-clinical concepts [GrownValve, June 2025]. Furthermore, its reliance on patient-derived tissue creates a potentially formidable regulatory and IP moat; the manufacturing process for a living, personalized implant is complex to replicate and may be protected as a regulated, patient-specific therapy. Early non-dilutive funding from the EIC Accelerator and German federal programs validates the technical premise and provides runway without excessive equity dilution [zabala.eu, 2026] [grownvalve.de, 2026].

This edge is perishable, however, and hinges on execution speed. The most significant exposure is to competitors with greater resources accelerating through clinical trials. Edwards Lifesciences and Medtronic have vast R&D budgets and established relationships with cardiology departments worldwide. A breakthrough in polymer science or tissue engineering from these incumbents could rapidly close the technological gap. Xeltis, with substantially more venture capital, may reach pivotal clinical endpoints and secure regulatory approval first, establishing the regenerative category standard. GrownValve also lacks the commercial infrastructure of its larger rivals; even with a successful product, it would likely need a partnership with a major device company for global distribution, which could compress margins and strategic control.

The 18-Month Scenario

The most plausible competitive scenario over the next 18 months centers on clinical data readouts and partnership announcements. The winner will be the company that can demonstrate not just safety, but compelling early efficacy and hemodynamic performance in its first-in-human cohort. If GrownValve can publish positive 12-month data from its initial patients showing valve function, integration, and no rejection, it will solidify its position as a leader in autologous regeneration and likely attract a significant Series A round or strategic investment. Conversely, if Xeltis announces a larger, multi-center trial with positive interim results, it could capture investor and clinician mindshare, positioning its scaffold-based approach as the more viable path to market.

The loser in this period is not necessarily the company with negative data, but the one that fails to generate any new, validating clinical milestones. For a capital-intensive, clinical-stage medtech, stalling progress makes fundraising prohibitively difficult. GrownValve's relatively modest $8 million seed round, while supplemented by grants, is small for the long clinical pathway ahead [PitchBook]. The risk is that without a timely Series A to fund a larger trial, the company loses momentum, allowing better-funded rivals to advance and potentially render its specific technical approach less distinctive.

Data Accuracy: YELLOW -- Competitor data is compiled from public company materials; GrownValve's funding and milestones are confirmed by PitchBook and company announcements. Direct, side-by-side clinical data comparisons are not yet publicly available.

Opportunity

PUBLIC The prize for GrownValve is a durable, high-margin position in a global heart valve replacement market where a single successful product can command a multi-billion dollar valuation.

The headline opportunity is to establish a new standard of care for pediatric and adult congenital heart valve disease, a segment where existing mechanical and bioprosthetic valves are fundamentally inadequate. The company's autologous valve, designed to grow and integrate with the patient, directly addresses the core clinical failure of current pediatric options: the need for multiple high-risk reoperations as a child grows. If GrownValve can demonstrate long-term safety and efficacy, it could become the default first-line therapy for a significant portion of the roughly 400,000 infants born annually with a heart valve defect, a patient population with no other durable solution [GrownValve, June 2025]. The first human implantation in June 2025 is the critical step from preclinical promise to clinical validation, moving the company toward this outcome.

Several concrete paths could lead to massive scale. The most direct is regulatory approval and adoption in the pediatric congenital market, a high-need segment with fewer competitors and potentially faster regulatory pathways under orphan device designations. Success there would create a beachhead for expansion into the larger adult valve market, particularly for younger patients seeking a lifelong solution. Another scenario involves the platform technology itself; the ability to create a patient-specific valve in a single operating room session suggests a future where the same core process could be adapted for other tubular organ structures, such as vascular grafts [LinkedIn, 2026].

Scenario	What happens	Catalyst	Why it's plausible
Pediatric Standard of Care	GrownValve becomes the default valve for congenital heart defect surgeries in children.	Successful completion of a pivotal clinical trial in pediatric patients.	The company is a spin-off from Charité and German Heart Center Berlin, institutions with deep pediatric cardiology expertise, and the technology's growth potential directly solves the pediatric reoperation problem [GrownValve, June 2025].
Platform Expansion	The autologous tissue engineering platform is validated for vascular grafts or other cardiac structures.	Publication of positive long-term data from the first human implant, demonstrating tissue integration and remodeling.	The core innovation is a patient-specific, regenerative construct; positive proof-of-concept in valves would de-risk application to similar anatomical challenges [Frontiers, 2026].

Compounding for GrownValve would manifest as a clinical data moat. Each successful implantation generates long-term patient data on valve performance, tissue integration, and growth. This dataset would be unique, impossible for competitors to replicate without running their own decade-long studies, and would continuously improve the company's predictive modeling for valve design and patient outcomes. Early signs of this flywheel are present in the preclinical research, where the procedure showed good valve functionality in a sheep model, providing the foundational data that supported the move to human trials [Frontiers, 2026].

The size of the win is framed by comparable public medtech companies. Edwards Lifesciences, a leader in transcatheter heart valves, holds a market capitalization exceeding $50 billion. While GrownValve is targeting a more specific patient population, a successful niche product in the structural heart space can still command significant value. For example, companies like CryoLife, focused on cardiac and vascular surgical implants, have been acquired for valuations in the $1-3 billion range. If GrownValve's pediatric scenario plays out and it captures a meaningful share of the congenital valve market, a valuation in the low billions is a plausible outcome (scenario, not a forecast). The adult valve replacement market is valued at over $10 billion globally, providing a clear ceiling for expansion [various analyst reports].

Data Accuracy: YELLOW -- The core opportunity thesis is built on the company's stated clinical target and the first human implantation milestone, which is confirmed. Market size comparables and platform expansion potential are inferred from the technology's described capabilities and established medtech valuation benchmarks.

Sources